文献速递胸部肿瘤

免疫肿瘤学时代的液体活检:是否已适合癌症患者的常规应用?

Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients?
PubMed 文献 · Ann Oncol · 2019-01-01

本综述讨论液体活检在免疫肿瘤学中的应用,用于预测接受免疫检查点抑制剂治疗患者的应答、复发或不良事件。循环肿瘤细胞、游离DNA、血浆蛋白与细胞因子及循环T淋巴细胞被讨论作为开发新免疫肿瘤学生物标志物的潜在来源。游离DNA定量及测序确定肿瘤突变负荷已较为成熟,循环肿瘤细胞、外泌体或血浆游离PD-L1定量及细胞因子检测也在积极研究中并已有 promising 结果发表。T淋巴细胞分析尤其是T细胞受体分析近期成为可能预测免疫检查点抑制剂应答的有价值生物标志物。液体活检尚未进入常规免疫肿瘤学临床实践,但近期 promising 数据和快速发展的技术表明该方法有潜力很快实现接受免疫检查点抑制剂癌症患者的个体化管理。

要点

  • 组织PD-L1免疫组化是目前晚期转移性癌症一线免疫治疗唯一验证的伴随诊断,但存在局限性。
  • 游离DNA定量作为预测生物标志物及其测序确定肿瘤突变负荷已较为成熟。
  • 循环肿瘤细胞、外泌体或血浆游离PD-L1定量及细胞因子检测正在积极研究中并有 promising 结果。

核心结论

  • 液体活检尚未在常规免疫肿瘤学临床实践中实施,但近期 promising 数据和快速发展的技术表明该方法有潜力很快实现接受免疫检查点抑制剂癌症患者的个体化管理。

研究设计与样本

  • 本综述讨论液体活检在免疫肿瘤学领域用于预测接受免疫检查点抑制剂(抗PD-1/PD-L1和CTLA-4)治疗患者的应答、复发或不良事件,并重点介绍近期进展。

主要发现

  • 循环肿瘤细胞、游离DNA、血浆中检测的蛋白质与细胞因子以及循环T淋巴细胞被讨论作为开发新免疫肿瘤学生物标志物的潜在来源。
  • 游离DNA定量作为预测生物标志物及其测序确定肿瘤突变负荷已较为成熟。
  • 循环肿瘤细胞、外泌体结合或血浆游离PD-L1定量以及细胞因子检测正在积极研究中,近期已发表 promising 结果。
  • T淋巴细胞分析尤其是T细胞受体分析近期成为可能预测免疫检查点抑制剂应答的有价值生物标志物。

临床怎么用

  • 液体活检尚未在常规免疫肿瘤学临床实践中实施。
  • 近期 promising 数据和快速发展的技术表明液体活检有潜力很快实现接受免疫检查点抑制剂癌症患者的个体化管理。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The emergence of immunotherapy in oncology requires the discovery, validation and subsequent adoption of robust, sensitive and specific predictive and prognostic biomarkers for daily practice. Until now, anti-PD-L1 immunohistochemistry (IHC) on tissue sections has been the only validated companion diagnostic test for first-line immunotherapy for advanced and metastatic cancer, notably non-small-cell lung cancer (NSCLC). However, detection of this biomarker presents limitations that have stimulated the development of other biomarkers and other approaches. Within this context, the use of a liquid biopsy (LB) could provide an important complementary or alternative added value to PD-L1 IHC. In this review, we discuss how LBs have been used in the field of immuno-oncology (I-O) to predict response, relapse or adverse advents for patients undergoing immune-checkpoint inhibitor (ICI) therapy (anti-PD-1/PD-L1 and CTLA-4) and we highlight recent developments. Circulating tumor cells (CTCs), cell-free DNA (cfDNA), proteins and cytokines detected in plasma as well as circulating T-lymphocytes are discussed as potential sources for developing new I-O biomarkers. The quantification of cfDNA as a predictive biomarker, as well as its sequencing for the determination of tumor mutational burden, is already well advanced. Additionally, the quantification of PD-L1 from CTCs, bound on exosomes or free in plasma, as well as the determination of cytokines, are also being actively investigated with promising results having recently been published. Lastly, analysis of T-lymphocytes, especially by analyzing the T-cell receptor, has recently emerged as a valuable biomarker that might become relevant for the prediction of response to ICIs. While LBs have not yet been implemented in routine I-O clinical practice, recent promising data and rapidly advancing technologies indicate that this approach has the potential to soon personalize the clinical management of cancer patients receiving ICIs.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Hofman P, Heeke S, Alix-Panabières C, et al. Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients? Ann Oncol. 2019. PMID: 31228184. doi:10.1093/annonc/mdz196

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。